MeiraGTx Holdings plc Asset Retirement Obligation, Accretion Expense
MeiraGTx Holdings plc (MGTX) reported Asset Retirement Obligation, Accretion Expense of $74.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AssetRetirementObligationAccretionExpense · last filed 2026-08-13
- MeiraGTx Holdings plc asset retirement obligation, accretion expense for the quarter ending 2026-06-30 was $38.00K, a 8.57% increase year-over-year.
- MeiraGTx Holdings plc asset retirement obligation, accretion expense for the quarter ending 2026-03-31 was $36.00K, a 42.86% decline year-over-year.
- MeiraGTx Holdings plc asset retirement obligation, accretion expense for the quarter ending 2025-12-31 was $27.00K, a 57.14% decline year-over-year.
- MeiraGTx Holdings plc asset retirement obligation, accretion expense for the quarter ending 2025-09-30 was $28.00K, a 42.86% decline year-over-year.
- MeiraGTx Holdings plc asset retirement obligation, accretion expense for fiscal 2025 was $153.00K, a 26.79% decline from fiscal 2024.
- MeiraGTx Holdings plc asset retirement obligation, accretion expense for fiscal 2024 was $209.00K, a 18.08% increase from fiscal 2023.
- MeiraGTx Holdings plc asset retirement obligation, accretion expense for fiscal 2023 was $177.00K, a 5.36% increase from fiscal 2022.
- MeiraGTx Holdings plc asset retirement obligation, accretion expense for fiscal 2022 was $168.00K.
| Period end | Asset Retirement Obligation, Accretion Expense 3 month | Asset Retirement Obligation, Accretion Expense 6 month | Asset Retirement Obligation, Accretion Expense 9 month | Asset Retirement Obligation, Accretion Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $38.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $74.00K 10-Q · filed 2026-08-13 | $101.00K derived: sum of 3 quarters · filed 2026-08-13 | $129.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $36.00K 10-Q · filed 2026-05-14 | $63.00K derived: sum of 2 quarters · filed 2026-05-14 | $91.00K derived: sum of 3 quarters · filed 2026-05-14 | $126.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $27.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $55.00K derived: sum of 2 quarters · filed 2026-03-30 | $90.00K derived: sum of 3 quarters · filed 2026-08-13 | $153.00K 10-K · filed 2026-03-30 |
| 2025-09-30 | $28.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $63.00K derived: sum of 2 quarters · filed 2026-08-13 | $126.00K 10-Q · filed 2025-11-13 | $189.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $35.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $98.00K 10-Q · filed 2026-08-13 | $161.00K derived: sum of 3 quarters · filed 2026-08-13 | $210.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $63.00K 10-Q · filed 2026-05-14 | $126.00K derived: sum of 2 quarters · filed 2026-05-14 | $175.00K derived: sum of 3 quarters · filed 2026-05-14 | $224.00K derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $63.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $112.00K derived: sum of 2 quarters · filed 2026-03-30 | $161.00K derived: sum of 3 quarters · filed 2026-03-30 | $209.00K 10-K · filed 2026-03-30 |
| 2024-09-30 | $49.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $98.00K derived: sum of 2 quarters · filed 2025-11-13 | $146.00K 10-Q · filed 2025-11-13 | $193.00K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $49.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $97.00K 10-Q · filed 2025-08-14 | $144.00K derived: sum of 3 quarters · filed 2025-08-14 | $185.00K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $48.00K 10-Q · filed 2025-05-13 | $95.00K derived: sum of 2 quarters · filed 2025-05-13 | $136.00K derived: sum of 3 quarters · filed 2025-05-13 | $181.00K derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $47.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $88.00K derived: sum of 2 quarters · filed 2025-03-13 | $133.00K derived: sum of 3 quarters · filed 2025-03-13 | $177.00K 10-K · filed 2025-03-13 |
| 2023-09-30 | $41.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $86.00K derived: sum of 2 quarters · filed 2024-11-13 | $130.00K 10-Q · filed 2024-11-13 | $173.00K derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $45.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $89.00K 10-Q · filed 2024-08-12 | $132.00K derived: sum of 3 quarters · filed 2024-08-12 | |
| 2023-03-31 | $44.00K 10-Q · filed 2024-05-09 | $87.00K derived: sum of 2 quarters · filed 2024-05-09 | ||
| 2022-12-31 | $43.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | $168.00K 10-K · filed 2024-03-15 | ||
| 2022-09-30 | $125.00K 10-Q · filed 2023-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |